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Pneumatosis cystoides intestinalis (PCI) is characterized by gas-filled cysts within
gastrointestinal tract wall from esophagus to rectum, with preferential involvement of
large and small intestine. PCI is rare with an estimated incidence of 0.03 to 0–2%
in general population. PCI can be distinguished into idiopathic (15%) or secondary
(85%) and the clinical picture ranges from completely asymptomatic to life-threatening
intraabdominal complications. Although etiology of PCI appears to be multifactorial,
the exact pathophysiology is poorly understood and two main theories have been
proposed (mechanical and bacterial). Over the last decades, an enormous therapeutic
armamentarium was considered in PCI’s management, including hyperbaric oxygen
therapy (HBOT). Treatment comprises conservative treatment in mild cases to surgery
in highly symptomatic and complicated PCI. In the late 70s, HBOT started to be
used in selected cases of PCI not responding to conservative measures. Since then,
several case reports, case series, and reviews have been published in the literature
with variable outcomes. The overall response rate and complete response were 92.1%
(n = 82/89) and 65.2% (n = 58/89), respectively, with a median follow-up of 7 months.
Furthermore, HBOT is extremely safe, with few reported complications in the literature
when used for PCI. Nevertheless, a randomized, controlled, and double-blind clinical trial
is unlikely to occur given the rarity of PCI, logistical issues of HBOT, and methodological
considerations related to adequate blinding with a sham-controlled group. HBOT in
combination with personalized diet and antibiotics may be beneficial for moderate to
severe PCI in patients with no indication for emergency exploratory laparotomy. The
purpose of this article is to synthesize the existing data, analyse results of previous
studies, identify gaps in knowledge, and discuss PCI’ management, including the
proposal of an algorithm, with a special focus on HBOT.
Keywords: pneumatosis cystoides intestinalis, pneumatosis intestinalis, pneumatosis coli, hyperbaric oxygen
therapy, hyperbaric oxygen, oxygen, treatment, review
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BACKGROUND
Pneumatosis cystoides intestinalis (PCI) was first described by
Johann George Du Vernoi (also known as Du Vernoy) in an
autopsy specimen in 1730 (1691–1759). The pioneering work
was published in the Commentaries of the Imperial Academy
of Science of Petersburg for the years 1730–1731 and printed
in 1738, entitled as “Aer intestinorum tam sub extima quam
intima tunica inclusus: observationes anatomicae” (1). In 1825,
Mayer coined the name of the disease as “pneumatosis cystoides
intestinorum,” which was adopted by several authors (2). In
1899, Hahn reported the first PCI in a living person (3). In
the literature PCI is described under different denominations,
including pneumatosis intestinalis, pneumatosis coli, cystic
lymphopneumatosis, peritoneal lymphopneumatosis, intestinal
emphysema, intestinal bullous emphysema, pseudolipomatosis,
gas cysts of the intestines, and intraluminal gas (4, 5).
The overall incidence of PCI is not precisely known, with
some studies showing rates of 0.03 (two cases among 6,553
patients in serial autopsy studies) to 0.2% (two cases in
1,900 examinations) (5–9). Furthermore, PCI detection seems
to be increasing with therapeutic arsenal expansion and a
higher number of complementary diagnostic exams and surgical
procedures performed (10). Nevertheless, the exact rate is not
possible to determine as many asymptomatic cases are beyond
the clinical scope (5). PCI in adults typically presents in the fourth
to eight decades (4, 10, 11). In an Asiatic database systematic
review, the peak age at onset was 45.3± 15.6 (ranged, 2–81) years,
male to female ratio of 2.4:1 and the average disease course of 6
months (11).
PCI is characterized by gas-filled cysts within gastrointestinal
tract wall from esophagus to rectum, with preferential
involvement of the large and small intestine (4, 5, 8–12).
Cysts may be confined to mucosa, submucosa, or subserosa, or
involve all the three layers. Subserous cysts are most frequently
observed in small intestinal pneumatosis, while submucous cysts
in colonic pneumatosis (12).
Although etiology of PCI appears to be multifactorial, the
exact pathophysiology is poorly understood and two main
theories have been proposed (mechanical and bacterial) (4, 5, 8–
11). PCI can be distinguished into idiopathic or secondary and
the clinical picture ranges from completely asymptomatic to life-
threatening intraabdominal complications (4, 5, 8–10, 13). PCI’s
management is generally conservative for patients with mild to
moderate symptoms and invasive procedures are reserved for
those refractories to medical therapy or who have developed
complications (4, 5, 9, 10, 13).
Hyperbaric oxygen therapy (HBOT) started to be used in
selected cases of PCI not responding to conservative measures
(5, 14). The rationale for HBOT clinical benefit in PCI is related
to the dissolution of the gas-filled cysts and the antimicrobial
activity, particularly for anaerobes gas-producing bacteria
(5, 14, 15).
With the lack of large randomized control studies to guide
the use of HBOT in the treatment of PCI, the goal of this
review is to synthesize the existing data, analyse results of
previous studies, identify gaps in knowledge, and discuss PCI’
management, including the proposal of an algorithm, with a
special focus on HBOT.
METHODS
Base on the evidence methodology of a scoping review, our aim
was to map and clarify the existing published literature on the
effectiveness of HBOT for the treatment of PCI. We choose
the scoping review as the best methodology for our research
objectives, which were to rapidlymap the existing literature, chart
data from the studies, and clarify concepts. We developed an a
priori protocol to define our main objective and methods. No
language nor date limits were applied. Search strategies included
review articles, clinical practice recommendations, case series,
case reports, images and supplemental files.
On January 6–8th 2021 published literature was searched
through the PubMed and Google Scholar, using two appropriate
controlled keywords: “pneumatosis” [MeSH] AND “hyperbaric
oxygen” [MeSH]. References from selected articles were scanned
in order to identify other papers.
Using Covidence (www.covidence.org), we inputted
our inclusion/exclusion criteria and selected the articles
independently by two reviewers (PMD, JVB).
The inclusion criteria defined included: (1) review articles of
PCI; (2) articles and expert meetings reporting clinical practice
recommendations for PCI’ management; (3) articles reporting
the physiological effects of oxygen on PCI; (4) case series of
patients with PCI treated with HBOT; (5) case reports of patients
with PCI treated with HBOT; (6) articles/abstracts must be
available with full-text.
The exclusion criteria were: (1) ongoing study and abstracts
were excluded; (2) case reports that only included normobaric
oxygen; (3) case reports in which the response to HBOT had
not been determined (exceptionally, data could be accepted if the
PCI’ therapeutic protocol had been suspended due to HBOT side
effect); (4) articles not mentioning PCI and/or HBOT at all.
For each case report the information concerning patient’s
age and gender, underlying disease or risk factor for PCI,
other (previous) treatments, HBOT protocol, overall response
(improvement or resolution of symptoms), complete response
(resolution of symptoms) and follow-up period were retrieved
directly from the manuscript data.
Our final data managing was performed in Microsoft Excel
version 16.41 (20091302) using a data charting form developed
for our protocol.
RESULTS
Results were restricted to data available in English, French,
Portuguese, Hungarian, Mandarin and Japanese. Since the
majority of PCI case reports were in Japanese, the help
of an interpreter was required for a full-text reading. The
same was applied to an article published in Hungarian and
another in Mandarin. Afterwards, the screening and selection of
articles, quality assessment, and data extraction were performed
independently by two reviewers (PMD, JVB), according to
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the pre-planned inclusion and exclusion criteria. Conflicts
were resolved by a third party (DAC) when a consensus was
not reached.
The initial search yielded 652 citations in PubMed and Google
Scholar. Excluding duplicates, the number was reduced to 618.
Title screen reduced the selection to 389 papers for reviewing
abstracts, and 281 fulfilled the criteria for reading the full-
text. References from selected articles were scanned in order
to identify other 10 papers. In the final selection, 105 articles
were chosen to be included in this review. Excluding literature
reviews and duplication of data published in different articles,
our assessment of the HBOT effectiveness for the treatment of
PCI was based on 74 case series and case reports from 1978 to
2020 (Figure 1) (Supplementary Material).
We evaluated 89 patients with PCI treated with HBOT.
Patient median age was 53 (0.8–98) years, of whom the
majority 49 (55.1%) were female. Eighty-one percent (n =
73) had at least one underlying disease or risk factor for
PCI. In this subgroup of patients, the predisposing factors
were divided into different categories: pulmonary disorders (n
= 10), mucosal disruption (n = 30), gastrointestinal motility
disorders (n = 13), malignancies (n = 10), infectious (n =
5), immunological disturbances (n = 26), iatrogenic causes (n
= 44) and intraabdominal complications (n = 3). In 18% of
the patients (n = 16), the possible etiology for PCI was not
discriminated in the previous past history and in some cases,
it was even considered to be idiopathic. Almost half of the
patients (n = 41; 45.5%) were treated previously or concurrently
with other complementary treatment measures, including bowel
rest, elemental diet, parenteral nutrition, antimotility agents,
antacids, antimicrobials, anti-inflammatory drugs, normobaric
oxygen and surgery. Administration of HBOT varied by study.
Atmospheric pressure ranged from 1.9 to 3 atmosphere absolute
(ATA), with a mean and median of 2.3 ATA and 2 ATA,
respectively. Duration of exposures and number of HBOT
sessions ranged from 40 to 150min (min) and 1 to 80 treatment
sessions, respectively. Beyond these protocols, six patients
underwent treatment tables more adapted to decompression
FIGURE 1 | Flowchart explaining the article selection strategy (adapted from PRISMA, 2009). HBOT, hyperbaric oxygen therapy; PCI, pneumatosis
cystoides intestinalis.
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Pulmonary disorders (n = 10): asthma (n = 5), chronic
obstructive pulmonary disease (n = 2), interstitial pneumonia
(n = 2), thymectomy (n =1)
Mucosal disruption (n = 30): corrosive agents (n = 14),
gastro-esophageal reflux disease/peptic ulcer disease (n = 6),
inflammatory bowel disease (n = 4), endoscopic procedures
(n = 2), prolapse rectal (n = 2), anorexia nervosa (n = 1),
feeding jejunostomy (n = 1)
Gastrointestinal motility disorders (n = 13): diabetes mellitus
(n = 6), paralytic ileus (n = 2), achalasia (n = 1), chronic
abdominal pain (n = 1), chronic constipation (n = 1), chronic
idiopathic intestinal pseudo-obstruction (n = 1), gastroparesis
(n = 1)
Malignancies (n = 10): leukemia (n = 4), colon cancer (n = 2),
cervix cancer (n = 1), gastric cancer (n = 1), head and neck
cancer (n = 1), kidney cancer (n = 1)
Infectious (n = 5): Clostridium difficile (n = 1), Clostridium
septicum (n = 1), Mycobacterium spp. (n = 1), Salmonella
spp. (n = 1), cytomegalovirus (n = 1)
Immunological disturbances (n = 26): (rheumatoid) arthritis
(n = 7), scleroderma (n = 5), polymyositis (n = 3), systemic
lupus erythematosus (n = 3), Sjögren syndrome (n = 2),
amyloidosis (n = 1), dermatomyositis (n = 1), granulomatosis
with polyangiitis (Wegener granulomatosis) (n = 1),
haemolytic anemia (n = 1), myasthenia gravis, Raynaud’s
phenomenon (n = 1)
Iatrogenic causes (n = 44): steroids (n = 14), abdominal
surgery (n = 10), other immunosuppressors (n = 7),
chemotherapy agents (n = 4), NSAIDs (n = 3), organ
transplantation (n = 3), targeted agents (n = 2), ionizing
radiation (n = 1)
Intraabdominal complications (n = 3): decompression
sickness (n = 2), intussusception (n= 1)
Other (previous)
treatments
Antimicrobials (n = 21)
Bowel rest (n = 10)
Antacids/Antimotility agents (n = 8)
Normobaric oxygen (n = 7)
Parenteral nutrition (n = 7)
Anti-inflammatory drugs (n = 7)
Elemental (personalized) diet (n = 4)
Surgery (n = 1)
HBOT protocol









92.1% (n = 82)
Complete
response









HBOT side effects Hearing disorder (n = 1)
Other (adverse)
outcomes
Intestinal surgery (n = 6)
Gastric cancer surgery (n =1)
PBSCT (n = 1)
Death of an unknown cause (n = 1)
ATA, atmosphere absolute; HBOT, hyperbaric oxygen therapy; Min, minute; Mos, months;
NSAIDs, non-steroidal anti-inflammatory drugs; PBSCT, peripheral blood stem cell
transplantation; Yrs, years.
sickness [Comex 30 - heliox 50/50 (16) and US Navy Treatment
Table 6 - USN TT6 and USN TT6A (17–19)]. In about 1/3 (n
= 37) of the cases it was not possible to identify clearly the
HBOT protocol regimen. Overall response rate (improvement
or resolution of symptoms) was achieved in 92.1% (82 of
89) patients. Complete response (resolution of symptoms)
was objectified in 65.2% (58 of 89) patients. There was one
immediately complication related to HBOT (hearing disorder).
(11) Other (adverse) events occurred during the peri-HBOT
period (n= 9): death of an unknown cause (20), peripheral blood
stem cell transplantation after (re)induction chemotherapy (21),
one gastric cancer surgery (22) and six surgeries for complicated
PCI (8, 23–27). Median follow-up was seven (0.5–120) months
(2/3 of the patients lost to follow-up) (Table 1).
DISCUSSION
Pathophysiology
The explanatory theories regarding PCI’s pathogenesis
are distinctly different in nature, but they also end up
being intersected, with mechanisms involving increased
transabdominal/intraluminal pressure, gut mucosal disruption,
increased mucosal permeability and gas-producing bacteria. The
current knowledge relies on two main theories – mechanical and
bacterial (Figure 2).
Clinical Presentation
Koss et al. (35) subcategorised PCI into primary/idiopathic
(15%) or secondary (85%). PCI can be secondary to a wide of
underlying conditions or predisposing factors: pulmonary
disorders, mucosal disruption, gastrointestinal motility
disorders, malignancies, infectious, immunological disturbances,
iatrogenic causes and intraabdominal complications.
Secondary PCI is traditionally divided into two categories:
benign or non-urgent and life-threatening causes (Table 2)
(4, 5, 8–11, 14–27, 29, 34–82).
As previously mentioned, PCI can be diagnosed by chance
in asymptomatic patients, while in others, it can be manifested
with a plethora of constitutional and gastrointestinal symptoms.
PCI-related symptoms are mainly related to the affected
gastrointestinal tract region and the underlying condition
that led to its onset. In small intestine, the most frequent
symptoms are nausea, vomiting, abdominal bloating and
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FIGURE 2 | Schematic representation of the two most widely accepted theories for explaining PCI’s development. Mechanical theory (1–3). Migration of gas into the
bowel wall through different routes: (1) Mucosal disruption with disturbance of normal continuity (inflammation, ulceration, trauma and necrosis); (2) Increased
mucosal permeability due to defective immune barrier (immunodeficiency or immunosuppressive drugs); (3) Increased transabdominal/intraluminal pressure leading to
direct gas diffusion into an intact mucosal barrier (bowel obstruction, chronic obstructive pulmonary disease, trauma or vomiting). The association of pulmonary
disorders with PCI could be explained by the Macklin effect described in 1939 (28) and further studied by others (29). This pathophysiologic process consists in
several steps: alveolar rupture with air dissecting along peribronchovascular interstitial sheaths and interlobular septa; spreading of this pulmonary emphysema into
mediastinum; extension to retroperitoneum and mesenteric root, allowing air penetration across the bowel wall (4, 5, 8–11, 15, 16, 18, 28–30). Typically, a variable
combination of these factors will contribute to gas dissection into intramural compartments. Bacterial theory (4). There are two main complementary mechanisms to
explain the contribution of bacterial microbiota for intramural gas production: (4.1) Gas-forming bacteria that directly penetrate gastrointestinal mucosa and
submucosa (model tested and reproduced in laboratory with Clostridium perfringens). However, cysts appear to be sterile, since even after its rupture the
pneumoperitoneum is not complicated by peritonitis; (4.2) Fermentation of bacterial gut microbiota converts carbohydrates and other nutrients into hydrogen gas. As
the pressure of the intraluminal gas increases, there is a greater trend for it to migrate through the mucosa and become trapped in the submucosa. This phenomenon
of gas gradient between intestinal lumen and blood that overcomes the bowel wall resistance is called “counterperfusion supersaturation.” Cysts can have as high as
50% hydrogen and, in some patients with PCI, the level of respiratory hydrogen is higher than in controls (4, 5, 8–11, 14–18, 21, 25, 27, 30–34).
pain, weight loss and diarrhea and, in relation to colonic
pneumatosis, the symptoms are abdominal bloating and pain,
constipation, flatulence, diarrhea, tenesmus and haematochezia.
Intraabdominal complications of PCI occur in <5% of patients
and include bowel obstruction driven by the cyst per se,
intussusception, volvulus, adhesions or pneumoperitoneum after
air-filled cyst’s rupture, haematochezia due to mucosa ulceration,
and intestinal ischaemia (4, 5, 8–11, 13, 34, 69, 83).
PCI is usually detected on imaging or endoscopy performed
for evaluation of abdominal symptoms. The radiological findings
may be present on several imaging modalities. However,
computed tomography scan is more sensitive than plain
radiography, indicating a potential underlying cause and a better
distinction between an indolent and complicated PCI, such as
bowel wall thickening, dilated bowel, vessels occlusion, hepatic
portal or portomesenteric venous gas, ascites, etc. (Figure 3)
(5, 9, 10, 15, 18, 19, 26, 48, 57, 59, 60, 62, 66, 69, 79, 80).
Treatment
PCI may disappear spontaneously, persist for many years,
or relapse after treatment. However, there are no consensus
guidelines on PCI’s management. The therapeutic approach
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TABLE 2 | Causes of secondary pneumatosis cystoides intestinalis.
Pulmonary disorders Asthma crisis, blunt or penetrating thoracic trauma, bronchiectasis, chronic obstructive pulmonary disease, cystic fibrosis, positive-pressure
mechanical ventilation, pulmonary fibrosis, pulmonary tuberculosis, sarcoidosis, Valsalva manoeuvres (parturition, Boerhaave’ syndrome, and
epileptic seizures)
Mucosal disruption Abdominal surgery, inflammatory bowel disease, corrosive agents, gastrointestinal endoscopy, ionising radiation, jejunostomy tubes, peptic
ulcer disease, ruptured diverticulum, steroids
Gastrointestinal motility
disorders
Chronic idiopathic intestinal pseudo-obstruction, chronic constipation, diabetes mellitus, gastroparesis Hirschsprung’s disease, ileus, jejunoileal
bypass, obstruction/pyloric stenosis, scleroderma
Malignancies Gastrointestinal cancer, leukaemia and lymphoproliferative disorders
Infectious AIDS-associated enterocolitis (Cryptosporidium, Cytomegalovirus, Mycobacterium avium), Adenovirus, Candida albicans, Clostridium spp.,
Enterobacter spp., Klebsiella spp., Lactobacillus spp., Mycobacterium tuberculosis, Salmonella spp., SARS-CoV-2, Tropheryma whipplei,
Rotavirus, varicella zoster virus
Immunological
disturbances
AIDS, amyloidosis, bone marrow transplantation, corticosteroids, dermatomyositis, graft-versus-host disease, granulomatosis with polyangiitis
(Wegener granulomatosis), mixed connective tissue disorder, polyarteritis nodosa, polymyositis, rheumatoid arthritis, sarcoidosis, scleroderma,
Sjögren syndrome, solid organ transplantation, systemic lupus erythematosus
Iatrogenic causes Abdominal surgery, antiacid medications, barium enema, bone marrow transplantation, bowel preparation, chemotherapy agents, chloral
hydrate, gastrointestinal endoscopy, immunosuppressors, ionising radiation, jejunoileal bypass, jejunostomy tubes, lactulose, mechanical
ventilation, nonsteroidal anti-inflammatory drugs, postsurgical anastomosis, sclerotherapy, steroids, solid organ transplantation, sorbitol,
targeted therapy, α-glucosidase inhibitor
Intraabdominal
complications
Intestinal ischaemia, infarction, intussusception, obstruction, perforation, mesenteric vascular disease, necrotising enterocolitis, toxic
megacolon, blunt or penetrating abdominal trauma, decompression sickness
AIDS, acquired immunodeficiency syndrome; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2; Green color (benign/nonurgent)/Red color (life-threatening).
FIGURE 3 | Pretreatment images of a 59-year-old woman with PCI that underwent HBOT at our centre (69) (A) PCI’s endoscopic image of subepithelial nodular
elevations covered with mucosa of normal appearance (B) Abdominal computed tomography showing gas-filled cysts in the splenic flexure of the colon.
reflects the (still) scarce knowledge of its pathophysiology,
ranging from conservative treatment in mild and moderate
cases to exploratory laparotomy in highly symptomatic patients
with intraabdominal complications (4, 5, 9, 10, 13, 30, 34, 69,
83). Furthermore, a potentially reversible PCI’s secondary cause
must also be ruled out and treated (e.g., targeted therapy with
axitinib) (73).
Asymptomatic patients do not require any complementary
treatment (5, 54). Patients with mild symptoms can be managed
on an outpatient basis with a combination of antibiotics cycles
and an elemental diet (5, 34). Sclerotherapy has also been
used with success (4, 69). For patients with moderate to
severe symptoms, a combination of antibiotics, an elemental
diet and HBOT is suggested (5, 26, 42, 69, 83). Patients with
refractory symptoms and intraabdominal complications have
an indication for surgery approach (5, 18, 23–27, 69). Clinical
and radiological follow-up should be performed based on each
case-based analysis.
Hyperbaric Oxygen Therapy
HBOT is a treatment based on the inhalation of pure oxygen
(100%) in an environment with atmospheric pressure higher
than that existing at sea level (1 ATA). The HBOT sessions are
held inside hermetically sealed hyperbaric chambers, which are
classified as type IIb medical devices (Directive 93/42 ECC of
June 14, 1993, concerning medical devices). HBOT is used in
a number of clinical conditions as well as in professional and
military training. In clinical practice, HBOT usually involves
pressures higher than 1.4 ATA, frequently ranging between 2.0
and 2.5 ATA for 90 to 120 min (84).
Both normobaric and HBOT have been used to treat
PCI not responding to conservative measures. The rationale
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behind the beneficial action of oxygen is related to two main
physiological effects, addressing some of the aforementioned
pathophysiological mechanisms of PCI:
 The reduction in inert gases volume and diameter provided
by ambient pressure elevation (Boyle’s law), creates a pressure
gradient which promotes oxygen diffusion into the gas-filled
cysts, while hydrogen and nitrogen moves out. Hence, HBOT
may restore normal intestinal motility by removing luminal
and bowel wall gas. This mechanism is enhanced by HBOT
in relation to normobaric oxygen, given the greater diffusion
gradients generated by oxygen administered under pressure
(> 2 ATA) (5, 14, 17, 18, 34, 42, 69, 85, 86).
 Oxygen contributes to antimicrobial activity, especially
for obligate and facultative anaerobic gas-producing
bacteria, promoting bacteriostatic/bactericidal effects,
leukocyte diapedesis and phagocytosis. In addition, HBOT
potentiates the action of some antibiotics, increasing
their local concentration, which is why the combination
of these treatments makes sense in PCI’ management
(5, 15, 34, 44, 71, 87, 88).
The use of high concentrations of oxygen in the treatment
of gas containing cavities was first proposed in 1935 (89).
However, it was only in 1973 by Forgacs et al. (85) that oxygen
inhalation was successfully used in PCI’ treatment. At that time,
the therapeutic protocol comprised an intensive regimen with
normobaric oxygen therapy (5 h/day, 7 days) to achieve a PO2 of
200 to 300 mmHg. The drawback of this protocol was related to
the increased risk of pulmonary toxicity (11, 20, 34, 44, 48, 56, 85).
In the late 70s, Masterson et al. (14) used HBOT (2.5 ATA,
120min, 2 or 3 consecutive days) with a clinically significant
benefit in 2 patients with PCI. Since then, several case reports,
case series, and reviews have been published in the literature.
In 1991, Grieve and Unsworth (42) reported a series with
8 patients treated with HBOT. As there was no standard
regimen, the number, pressure and duration of treatment sessions
were variable (ranged, 6–11, 1.9–2.8 ATA and 70–135min,
respectively). With the exception of 2 patients, treatment sessions
were twice daily. All patients responded to treatment, with 4
long-term complete remissions. Two patients died of another
cause. In 2001, Shimada et al. (48), in a Japanese literature review,
reported the outcomes of 15 patients with PCI treated with
HBOT (2 to 3 ATA, 60 to 120 min/day, ranging from 3 to 33
days). PCI resolved in 11 patients, improved in the other 4, and
relapsed in 1 patient 9 months after treatment. There were no
serious adverse events registered. In 2004, in another Japanese
literature review, by Togawa et al. (54), outcomes were directly
compared among two groups of patients with PCI. Seven patients
underwent HBOT and 20 patients to normobaric oxygen with a
number of treatment days of 1–8 (mean, 4.7) and 1–35 (mean,
14.6), respectively. Despite the bias of a direct comparison,
a shorter treatment period required for HBOT patients may
suggest a better therapeutic effect. In 2005, Tahiri et al. (90),
proposed a different treatment approach based on decision-
making factors, such as clinical, laboratorial and imaging data,
considering HBOT in the absence of surgery indication. More
recently, in 2014, in the largest literature review published so
far, by Feuerstein JD et al. (5), 35 illustrative cases of PCI
treated with HBOT were identified. Symptomatic resolution or
improvement was achieved in 89% of patients (31/35). Although,
the therapeutic protocol was not uniform across the case reports.
These authors proposed a treatment regimen of HBOT at 2.5
ATA during 120min for at least 3 sessions in patients with
symptomatic and non-emergent PCI. After this Mayo Clinic
concise review (5), more case reports were published in the
literature (Supplementary Material) (5, 11, 14–27, 34, 36–81, 88,
91–101).
To the best of our knowledge, we included in our scoping
review the important studies regarding the effectiveness of HBOT
for PCI in the “real world” clinical practice. We considered 74
studies comprising 89 patients with PCI treated with HBOT,
including one patient of our center. In this 42-year analysis
the overall response rate and complete response were 92.1
and 65.2%, respectively, for a median follow-up of 7 (0.5–120)
months. These numbers reinforce the data assessment reported
in previous literature reviews. It should also be noted that almost
half of the patients were previously treated or concurrently with
other complementary treatments, evidencing the importance
of a multimodal approach of this gastrointestinal pathology.
However, a long-term follow-up evaluation is suggested to
determine the long-term outcome of HBOT and other treatments
in this setting.
Interestingly, the men-to-women ratio was not what would
be predictable according to what was published in one of the
largest population-based systematic reviews with 239 PCI cases
(11). On the contrary, the age of our cohort was in line with
what was published in the same study (11). These facts are
probably more related to the small sample size and to the possible
predisposing conditions for PCI, including, for example, the
immunological disturbances that are generally more frequent
in females (102). In this review, 28.9% of patients (26/90)
had a background autoimmune disease, and the majority were
female (only 2 males).
Despite the very favorable data on clinical benefit of HBOT
for PCI, it is difficult to compare the protocols that have
used different hyperbaric protocols regimens (PO2 pressures,
air intervals, duration of exposures and number of HBOT
sessions), various techniques for oxygen delivery (hood, mask,
monoplace) and several (or absent) complementary treatments
that were variable among the studies. In addition, differences
in the type of patients included in this review with different
ages, comorbidities and clinical conditions also contribute to
further consolidating this heterogeneity. The ATA level, duration
and number of HBOT sessions ranged from 1.9 to 3 ATA,
40 to 150min and 1 to 80 treatment sessions, respectively.
Different HBOT protocols (Comex 30 – heliox 50/50 and USN
TT 6/TT6A) were performed in six patients (16–19). These
types of treatment regimens that are better clinical validated
for severe decompression sickness and gas embolism, were used
in three cases of hydrogen peroxide ingestion (17) and in
another case with no apparent underlying cause for PCI, besides
chronic constipation (16). The complete response rate was 100%
in all these cases, with the exception of one of the cases of
severe decompression illness with mesenteric venous thrombosis
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and PCI (18). Despite the initial mitigation of intravenous gas
according to the image findings, the clinical course worsened
with the need for surgery and admission to the intensive care
unit (18). To avoid this outcome, could the treatment have been
intensified with increased pressure and duration of exposure?
Hence, bubbles of inert gas would be eliminated more quickly. In
the other case of severe decompression sickness, the compression
was upgraded to 6.0 ATA to fit the USN TT6A with a clear
improvement of symptoms (19). Probably in critically ill patients
with PCI following decompression sickness with no significant
improvement 30min after recompression at 2.8 ATA, treatment
should be further intensified.
There was one immediately complication related to HBOT
(hearing disorder) (11). Probably it was a tympanic barotrauma,
themost frequent HBOT side effect (103). During the peri-HBOT
period, we should highlight a death of an unknown cause (20), a
peripheral blood stem cell transplantation (21), 1 gastric cancer
surgery (22) and 6 surgeries for complicated PCI. (8, 23–27) The
patient who died had undergone HBOT a few days before with
improvement of PCI. However, shortly thereafter, the patient
worsened dramatically with pleural effusion, haemoptysis, severe
respiratory failure, and eventually died (20). Given that an
autopsy was not performed, it was not possible to determine
the cause of death. We can speculate that this fatal outcome
could have been related to the progression of head and neck
cancer with lung metastases or even, although being a more
remote hypothesis, with a pulmonary complication of HBOT.
In the case related to bone marrow transplantation, the patient
developed PCI after re-induction chemotherapy in the context
of an acute myeloid leukemia. The combination of HBOT with
broad-spectrum antimicrobial agents enabled the resolution of
PCI, avoiding delays that could impact the ideal timing for
transplantation (21). Interestingly, during the gastric cancer
surgery, it was witnessed the live response to HBOT in the
sigmoid and transverse colon with PCI. After 1 month, PCI
complete remission was observed (22). Six patients with slight
improvement or refractory symptoms to HBOT underwent
intestinal surgery.
Notwithstanding the clinical value of HBOT, when PCI is
secondary to gas entry via pulmonary disorders, there may be a
worsening of the clinical picture with intestinal expansion during
decompression. Thus, HBOT should be performed carefully in
these specific settings.
The current analysis is limited by several factors, including
its retrospective nature, evidence based on case reports,
population heterogeneity and incomplete registration data in
relation to the patient’s characteristics/outcomes and to the
clinical context of PCI and HBOT protocols. Nevertheless,
the authors believe that the current findings represent an
accurate depiction of the clinical effectiveness of HBOT for PCI,
FIGURE 4 | Suggested treatment algorithm for pneumatosis cystoides intestinalis. PCI, pneumatosis cystoides intestinalis.
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including in severe clinical conditions underrepresented in other
literature reviews.
With the growing requirement for evidence-based research,
HBOT has been criticized for delivering too little high-quality
research, mainly in the form of randomized controlled trials.
Nevertheless, the design of a sham (hyperbaric) treatment is
associated with considerations regarding adequate blinding and
the use of pressure and oxygen (104). Additionally, considering
the rarity of PCI and the logistical issues of HBOT, it is difficult to
admit that in the future it will be possible to conduct randomized
controlled clinical trials in this particular context. Currently,
HBOT is considered by the European Committee for Hyperbaric
Medicine (ECHM) as a modality of treatment for PCI (degree of
recommendation II/level of evidence C) (105).
We recommend that HBOT, in combination with elemental
diet and antibiotics, may be beneficial for patients with moderate
to severe symptoms and not requiring emergent exploratory
laparotomy. The HBOT regimen should include at least 3
sessions of 2 to 3 ATA and between 60 to 120 min/day to
ensure a more effective clinical response. The total duration of
the treatment protocol could be extended to several weeks until
clinical and radiological response and the follow-up should be
personalized to each clinical context.We suggest that radiological
follow-up be performed after symptoms control or every 3 to 6
months until the resolution of the imaging findings (Figure 4).
CONCLUSIONS
Herein, we reported the relevant literature review on PCI’s
epidemiology, pathophysiology, clinical presentation and
analyzing the results of previous HBOT studies and discussing
PCI’ management, including the proposal of an algorithm, which
takes into account the variables related to the patient, institution,
and clinical context severity.
Although the identification of the underlying cause of PCI is
crucial for the prognosis and treatment, it is not well-defined how
or if it affects HBOT’s response. HBOT probably addresses some
of the underlying PCI’s pathophysiological mechanisms. There
were an overall response rate and complete response rate of 92.1
and 65.2%, respectively, for a median follow-up of 7 months. The
optimal concentration, duration, and effect of oxygen have not
yet been precisely determined. A long-term follow-up evaluation
is suggested to determine the long-term outcome of HBOT and
other treatments in this setting.
There is a lack of randomized or prospective data on the
application of HBOT for PCI, and this would normally limit
the strength of recommendations for its use. A randomized,
controlled, and double-blind clinical trial is unlikely to occur
given the rarity of PCI, the logistical issues and the several
methodological considerations regarding adequate blinding with
the addition of a sham-controlled group. Although, despite
the absence of any high-level evidence, the resolution of
symptoms in most retrospective studies with HBOT may
support recommendations for its use as a treatment strategy
for PCI. Therefore, the publication of the experience from
different Hyperbaric Medicine Centers in PCI’s management is
essential to better validate its effectiveness in the “real world”
clinical practice.
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